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Endoscopic treatment for vesicoureteral reﬂux (VUR) has become an established alternative to long-term antibiotic prophylaxis
and ureteral reimplantation. We present the outcome of endoscopic treatment with dextranomer/hyaluronic acid copolymer
(Deﬂux) for VUR in children by a single surgeon at our institute from October 2003 to October 2009. We reviewed the cases
of 150 patients (total 239 ureters), 56 girls (37%) and 94 boys (63%), with a mean age of 2.2 years and a median followup of
2.5 years (range 3–68 months). Among the 239 ureters treated, 67.4% (161/239) were cured with a single injection, and a second
and third injection raised the cure rate to 86.6% (207/239) and 88.3% (211/239), respectively. None had postoperative ureteral
obstruction.
1.Introduction
Vesicoureteric reﬂux (VUR) is a common problem encoun-
tered by pediatric urologists. Traditionally, if medical man-
agement with low-dose antibiotic prophylaxis failed, the
only alternative was ureteral reimplant surgery [1]. Since
Matouschek’s initial description of the subureteric injection
technique in 1981 [2] and the ﬁrst clinical series reported
by O’Donnell and Puri in 1984 [3] , it has evolved into
a therapeutic alternative to ureterocystostomy. Injectable
agents, such as Teﬂon, bovine collagen, and Macroplastique,
have all been used; however, concerns about eﬃcacy and
safety have limited their use [1, 4–6]. Since the ﬁrst
introduction into clinical use by Stenberg and L¨ ackgren in
1995, dextranomer/hyaluronic acid copolymer (Deﬂux) has
become an established alternative treatment for VUR in
children [1]. We present the recent results of endoscopic
treatment using the subtrigonal injection of Deﬂux for VUR
in children by the same operator at our institute.
2.MaterialsandMethods
We retrospectively reviewed all cases of subtrigonal injection
performed with Deﬂux from October 2003 to October
2009 at Taichung Veteran General Hospital. All patients
who entered into the study had vesicoureteric reﬂux, as
determined by voiding cystourethrogram (VCUG). The
radiological grading of VUR is according to the international
system introduced by the International Reﬂux Study Com-
mittee in 1985 [7]. A total of 150 children, 1 month to 10
years old (mean age 2.2 years), received subtrigonal injection
of Deﬂux for VUR. A subureteral or intraureteral injection,
at the 6 o’clock position, delivered the material to correct
VUR. Indications for intervention included breakthrough
urinary tract infection, progressive renal scarring, poor
compliance with medical therapy, nonresolution of VUR
(>2 years), and parental preference [1, 2, 8]. Patients with
more complicated urinary anomalies, such as ectopic ureter
and neurogenic bladder, were also included. All procedures2 Diagnostic and Therapeutic Endoscopy
Table 1: The treatment results of various VUR grading in our patients.
Grade of
VUR





open surgery 1 inj. 2 inj. 3 inj. 4 Inj.
I 9 9 (100%) 0 0 0 — 0.1–1mL (0.6) 0
II 44 33 (75%) 7 (16%) 0 0 3 (7%) 0.2–1.3mL (0.6) 1 (2%)
III 113 86 (76%) 18 (16%) 0 0 4 (4%) 0.1–1.7mL (0.7) 5 (4%)
IV 57 31 (54%) 15 (26%) 2 (4%) 1 (2%) 2 (4%) 0.1–1.7mL (0.9) 6 (10%)
V 16 2 (13%) 6 (38%) 2 (13%) 0 3 (18%) 0.3–2.3mL (1.0) 3 (18%)
Table 2: Endoscopic treatment with Deﬂux for primary VUR in diﬀerent series.
Series Ureters Injected volume Followup Success rate
Puri et al. [9] 1101 0.2–1.5mL 3–46mo 96%
Kirsch et al. [10] 139 0.8–2mL 3–18mo 93%
Yu and Roth [11] 162 1mL 2–26mo 93%
Pinto et al. [12] 86 3mo 84%
Chen (2010) 239 0.1–2.3mL 3–68mo 88%
Table 3: Endoscopic treatment with Deﬂux for high grade VUR in diﬀerent series.
Series Ureters Success rate Downgrade to Gr. I Conversion to op
one inj. > one inj.
Kirsch et al. [5] 119 71–90%
Dawrant et al. [13] 642 73% 16% 9% 2%
Menezes and Puri [14] 467 80% 16% 4% 0%
Altug et al. [15] 133 55% 19%
Chen (2010) 73 45% 36% 7% 12%
were carried out as day surgery, with the patients under
general anesthetic. The procedures were all performed by the
same surgeon. The technique comprises a hydrodistention-
implantation technique with subureteric or intraureteric
transurethral injection of Deﬂux with a Fr. 9.5 pediatric
cystoscope, which is the same as the technique described in
the literatures until we obtained a “bulge” with an elevated,
inverted crescent shape of the oriﬁce [4, 16]. Patients
were maintained on their antibiotic prophylaxis until reﬂux
was documented to be absent on postoperative VCUG or
radionuclide cystogram at 3 months after injection. Patients
were observed with dimercapto-succinic acid (DMSA) renal
scan at the interval of 12 weeks postoperatively after surgery.
Patients who failed initial injection were oﬀered continued
observation, a second injection, or ureteroneocystostomy.
T h eo u t c o m e sw e r ea n a l y z e do v e r a l l ,a n das u b g r o u p
analysis was carried out for patients with high grade VUR
(grade IV to V).
3. Results
One hundred and ﬁfty patients, 56 girls (37%) and 94 boys
(63%), with a mean age of 2.2 years (range 1mo–10yr)
underwent subtrigonal injection with Deﬂux from October
2003 to October 2009. Median followup duration was 2.5
yearsandrangedfrom3to68months.Eightypatients(53%)
had bilateral VUR, 61 (41%) had unilateral VUR, and 9
(6%) had new contralateral VUR for a total of 239 ureters
treated with a median followup of 2.5 years (range 2–62mo).
There are 9 (3.8%) ureters graded as I, 44 (18.4%) as II,
113 (47.3%) as III, 57 (23.8%) as IV, and 16 (6.7%) as
V. The VCUG or radionuclide cystogram followup showed
that the overall cure rate was 88.3% (211/239). The detail
of the patients’ data is shown in Table 1. Among the 239
ureters, 67.4% (161/239) were cured with a single injection.
A second and third injection raised the cure rate to 86.6%
(207/239) and 88.3% (211/239), respectively. Cure rate for
grade I was 100% (9/9), grade II 91% (40/44), grade III
92% (104/113), grade IV 86% (49/57), and grade V 64%
(10/16). One patient with unilateral grade IV VUR had 4
injections and then was cured. There were 143 children (229
ureters) with primary VUR, 2 children (3 ureters) with VUR
secondary to neurogenic bladder, 2 children (3 ureters) with
VUR secondary to ectopic kidneys, 2 children (2 ureters)
with complex VUR, and one child (2 ureters) with VUR due
to failed open ureteroneocystostomy. No ureter had postop-
e r a t i v eu r e t e r a lo b s t r u c t i o n .O n eh a dp o s t o p e r a t i v ef e b r i l e
UTI and subsided after intravenous antibiotic treatment.
One had postoperative urinary retention and subsided after
oral analgesic agents.
There were 73 ureters with high grade VUR, including 57
with grade IV VUR and 16 with grade V VUR. Overall cureDiagnostic and Therapeutic Endoscopy 3
rate was 80.8% (59/73), 5 (6.9%) ureters were downgraded
to grade I, and 9 (12.3%) converted to open ureteral
reimplantation. Complete resolution of vesicoureteral reﬂux
after a single injection occurred in 33 ureters (45%), and 26
(36%) required more than 1 injection to correct VUR. No
patients had postoperative vesicoureteral obstruction, gross
hematuria, and febrile UTI.
4. Discussion
Our series demonstrates an overall patient cure rate of 88.3%
(211/239)oftheuretersamongthosewhowerecuredneeded
more than a single injection. In addition, approximate
5% (12/239) was downgraded to grade I, and no further
treatment was needed. These results are acceptable when
we compare the cure rate obtained by other series shown
in Table 2 or by open surgery, especially if we take into
account the noninvasive nature of the technique [1, 5, 16].
Endoscopic treatment of high grade VUR has been evaluated
in some series, and success rates vary from 55% to 90% [1].
In general, cure rates for high grade VUR are lower than
that for low to moderate VUR whereas endoscopic treatment
with Deﬂux has become an eﬀective alternative to open
ureteral reimplantation for high grade VUR [1]. The results
of diﬀerent series are shown in Table 3.
The complication rate in this series was low. Contralat-
eral low-grade de novo VUR was present in 6% (9/239) of
the patients treated for unilateral VUR—an incidence rate
comparable to a previous report [1]. Conversion to open
ureteral reimplantation was observed in 12 patients (8%),
but the most common indications in our patients are due
to parental decision and parental economic factor instead
of a truly failed treatment. Ureteral obstruction has been
described as a nonfrequent and temporary complication,
and clinically none was observed in our series. Hematuria
was absent or mild in most children and was limited
to the ﬁrst day postinjection [8]. The limitations of our
study include that the data collected in the charts may be
biased.
5. Conclusion
Endoscopic correction is a safe, eﬀective, and minimally
invasive outpatient procedure for VUR in children. It
demonstrated a cure rate of approximately 92% (138/150) of
patients and 88% (211/239) of the ureters by using the bulk-
ingagent,Deﬂuxbyanexperiencedsurgeon.Evenhighgrade
VUR, complex VUR, and failed open ureteroneocystostomy
do not seem to adversely aﬀect results.
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